Sexually Transmitted Diseases

A recent study has found that 1 in 9 men living in the United States have oral HPV.

Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.

Dr. Shibani Mukerji discusses how HIV affects the brain as part of a symposium at ID Week 2017.

A new literature review of 60 papers and studies finds that voluntary medical male circumcision programs in Africa also have benefits for women’s health.

NIAID director Dr. Anthony S. Fauci stresses in a recent commentary that, from a practical standpoint, the development of a moderately effective HIV vaccine is “essential” to ending the pandemic.

A total of 5 HIV cure research initiatives will receive $7.5 million as recipients of Gilead’s HIV cure grants program.

Recent research reveals that the composition of a woman’s vaginal microbial makeup—specifically, a preponderance of the bacteria Lactobacillus iners—may mean she’s more likely to be infected with Chlamydia trachomatis.

Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.

Jessica Justman, MD, shares how the PHIA project is collecting HIV biomarkers in children.

One survey found that fewer than 60% of 18- to 24-year-olds regularly use condoms during sexual encounters.

Having herpes simplex 2 puts individuals at greater risk of contracting HIV, and vice versa, largely due to increased genital ulceration and viral shedding.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Investigators presented advances in basic and clinical research on infectious diseases and HIV in the past year at ID Week.

The results of a 5-year study show that coffee drinking can cut down the risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) infections.

A Phase 2 study showed that maraviroc-containing antiretroviral regimens were generally safe and well-tolerated in a female population.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.

Death rates among HIV-positive patients diagnosed with cryptococcal meningitis were slightly lower when antiretroviral therapy was delayed a few weeks after diagnosis.

Made of a flexible silicone material, the ring contains dapivirine, a non-nucleoside reverse transcriptase inhibitor that blocks HIV’s ability to replicate inside of a healthy cell.

The CDC’s most recent Sexually Transmitted Disease Surveillance Report shows that the rates of sexually transmitted diseases have reached a record high in the United States.

New research on Zika virus transmission leads some investigators to suggest that the virus should be labeled a sexually transmitted infection.

Case Western Reserve University School of Medicine researchers identify accentuated risks for age-associated comorbidities in those living with HIV.

Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.

Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.

Janssen Research & Development submits a new drug application for a darunavir-based once-daily, single-tablet regimen for the treatment of HIV in adults and adolescents 12 years and older.